Type I-like behavior of the type II α7 nicotinic acetylcholine receptor positive allosteric modulator A-867744.
A-867744
Choline
Cognitive enhancement
PNU-120596
Patch clamp
Positive allosteric modulator
Type II PAM
α7 nAChR
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
03
2019
accepted:
24
07
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
20
9
2019
Statut:
epublish
Résumé
Cognitive impairment often involves the decreased expression or hypofunction of alpha 7-type nicotinic acetylcholine receptors (α7 nAChRs). Agonists or positive allosteric modulators (PAMs) of α7 nAChRs are known to be potential treatments for dementias, different neurodegenerative disorders, pain syndromes and conditions involving inflammation. In some of these conditions, it is desirable to maintain the temporal precision of fast cholinergic events, while in others, this temporal precision is unnecessary. For this reason, the optimal therapeutic effect for distinct indications may require PAMs with different mechanisms of action. The two major mechanisms are called "type I", which are compounds that augment α7 nAChR-mediated currents but maintain their characteristic fast kinetics; and "type II", which are compounds that produce augmented and prolonged currents. In this study, we performed a kinetic analysis of two type II PAMs of the α7 nAChR: PNU-120596 and A-867744, using a fast perfusion method that allowed high temporal resolution. We characterized the type of modulation produced by the two compounds, the state-dependence of the modulatory action, and the interaction between the two compounds. We found fundamental differences between the modulation mechanisms by PNU-120596 and A-867744. Most importantly, during brief agonist pulses, A-867744 caused a strikingly type I-like modulation, while PNU-120596 caused a type II-like prolonged activation. Our results demonstrate that specific compounds, even though all labeled as type II PAMs, can behave in completely different ways, including their onset and offset kinetics, state preference, and single channel open time. Our results emphasize that subtle details of the mechanism of action may be significant in assessing the therapeutic applicability of α7 nAChR PAM compounds.
Identifiants
pubmed: 31534841
doi: 10.7717/peerj.7542
pii: 7542
pmc: PMC6727837
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e7542Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
Mol Med. 2003 May-Aug;9(5-8):125-34
pubmed: 14571320
J Biol Chem. 2005 Jan 14;280(2):1257-63
pubmed: 15504725
J Neurosci. 2005 Apr 27;25(17):4396-405
pubmed: 15858066
Mol Pharmacol. 2007 Sep;72(3):715-24
pubmed: 17565004
Recent Pat CNS Drug Discov. 2007 Jun;2(2):99-106
pubmed: 18221220
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14686-91
pubmed: 18791069
Physiol Rev. 2009 Jan;89(1):73-120
pubmed: 19126755
J Pharmacol Exp Ther. 2009 Jul;330(1):257-67
pubmed: 19389923
Curr Pharm Des. 2010 Jan;16(3):323-43
pubmed: 20109142
Biochemistry. 2011 Jun 14;50(23):5263-78
pubmed: 21510634
Biochem Pharmacol. 2011 Oct 15;82(8):915-30
pubmed: 21575610
Biochem Pharmacol. 2011 Oct 15;82(8):891-903
pubmed: 21741954
Neuropharmacology. 2011 Dec;61(8):1306-13
pubmed: 21820451
Mol Pharmacol. 2011 Dec;80(6):1013-32
pubmed: 21885620
J Neurosci. 2011 Sep 28;31(39):13870-9
pubmed: 21957249
J Neurochem. 2012 Oct;123(1):73-83
pubmed: 22804734
PLoS Comput Biol. 2012;8(10):e1002721
pubmed: 23093920
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6595-600
pubmed: 23576748
Neuropharmacology. 2014 Jun;81:42-54
pubmed: 24486377
Neuropharmacology. 2014 Jun;81:101-15
pubmed: 24486379
Eur J Pharmacol. 2014 Mar 15;727:181-5
pubmed: 24530419
Neuropharmacology. 2015 Sep;96(Pt B):302-11
pubmed: 25460185
Neuropharmacology. 2015 Oct;97:75-85
pubmed: 25998276
Chem Biol. 2015 Aug 20;22(8):1063-73
pubmed: 26211363
Biochem Pharmacol. 2015 Oct 15;97(4):408-417
pubmed: 26231943
Prog Neurobiol. 2016 Sep;144:142-57
pubmed: 26797042
Neuropharmacology. 2016 Aug;107:189-200
pubmed: 26926428
Cell Mol Life Sci. 2016 Jul;73(13):2511-30
pubmed: 26979166
Mol Pharmacol. 2016 Sep;90(3):288-99
pubmed: 27190210
Pharmacol Ther. 2017 Nov;179:1-16
pubmed: 28529069
J Physiol. 2018 May 15;596(10):1847-1861
pubmed: 29131336
Mol Pharmacol. 2018 Feb;93(2):128-140
pubmed: 29196491